November 21, 2016 - By Clifton Ray · 0 Comments
The stock of Xbiotech Incorporated (NASDAQ:XBIT) registered an increase of 6.49% in short interest. XBIT’s total short interest was 3.99M shares in November as published by FINRA. Its up 6.49% from 3.75M shares, reported previously. With 95,900 shares average volume, it will take short sellers 42 days to cover their XBIT’s short positions. The short interest to Xbiotech Incorporated’s float is 22.86%. About 89,090 shares traded hands. XBiotech Inc (NASDAQ:XBIT) has risen 11.76% since April 19, 2016 and is uptrending. It has outperformed by 7.90% the S&P500.
XBiotech Inc. is a clinical-stage biopharmaceutical company. The company has a market cap of $452.68 million. The Firm is engaged in discovering and developing True Human monoclonal antibodies for treating a range of diseases. It currently has negative earnings. The Firm focuses on bringing its lead product candidate, Xilonix , to market.
XBiotech Inc., incorporated on October 23, 2005, is a clinical-stage biopharmaceutical company. The Firm is engaged in discovering and developing True Human monoclonal antibodies for treating a range of diseases. The Firm focuses on bringing its lead product candidate, Xilonix (MABp1), to market. The Firm has also developed a True Human monoclonal antibody discovery platform and manufacturing system. The Company’s therapeutic antibody, Xilonix, is being evaluated as a monotherapy to treat advanced stages of colorectal cancer. Xilonix neutralizes a pro-inflammatory protein produced by leukocytes and other cells, interleukin-1 alpha (IL-1a).
More recent XBiotech Inc (NASDAQ:XBIT) news were published by: Marketwatch.com which released: “XBiotech Inc. NASDAQ: XBIT” on April 15, 2015. Also Fool.com published the news titled: “Why XBiotech Inc. Fell 33% Today” on July 05, 2016. Fool.com‘s news article titled: “Why XBiotech Inc. Made a U-Turn Today” with publication date: December 08, 2015 was also an interesting one.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Clifton Ray